RT Journal Article
SR Electronic
T1 Detection and surveillance of SARS-CoV-2 genomic variants in wastewater
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.08.21249379
DO 10.1101/2021.01.08.21249379
A1 Katharina Jahn
A1 David Dreifuss
A1 Ivan Topolsky
A1 Anina Kull
A1 Pravin Ganesanandamoorthy
A1 Xavier Fernandez-Cassi
A1 Carola Bänziger
A1 Alexander J. Devaux
A1 Elyse Stachler
A1 Lea Caduff
A1 Federica Cariti
A1 Alex Tuñas Corzón
A1 Lara Fuhrmann
A1 Chaoran Chen
A1 Kim Philipp Jablonski
A1 Sarah Nadeau
A1 Mirjam Feldkamp
A1 Christian Beisel
A1 Catharine Aquino
A1 Tanja Stadler
A1 Christoph Ort
A1 Tamar Kohn
A1 Timothy R. Julian
A1 Niko Beerenwinkel
YR 2021
UL http://medrxiv.org/content/early/2021/07/15/2021.01.08.21249379.abstract
AB The emergence of SARS-CoV-2 mutants with altered transmissibility, virulence, or immunogenicity emphasizes the need for early detection and epidemiological surveillance of genomic variants. Wastewater samples provide an opportunity to assess circulating viral lineages in the community. We performed genomic sequencing of 122 wastewater samples from three locations in Switzerland to analyze the B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2 on a population level. We called variant-specific signature mutations and monitored variant prevalence in the local population over time. To enable early detection of emerging variants, we developed a bioinformatics tool that uses read pairs carrying multiple signature mutations as a robust indicator of low-frequency variants. We further devised a statistical approach to estimate the transmission fitness advantage, a key epidemiological parameter indicating the speed at which a variant spreads through the population, and compared the wastewater-based findings to those derived from clinical samples. We found that the local outbreak of the B.1.1.7 variant in two Swiss cities was observable in wastewater up to 8 days before its first detection in clinical samples. We detected a high prevalence of the B.1.1.7 variant in an alpine ski resort popular among British tourists in December 2020, a time when the variant was still very rare in Switzerland. We found no evidence of local spread of the B.1.351 and P.1 variants at the monitored locations until the end of the study (mid February) which is consistent with clinical samples. Estimation of local variant prevalence performs equally well or better for wastewater samples as for a much larger number of clinical samples. We found that the transmission fitness advantage of B.1.1.7, i.e. the relative change of its reproductive number, can be estimated earlier and based on substantially fewer wastewater samples as compared to using clinical samples. Our results show that genomic sequencing of wastewater samples can detect, monitor, and evaluate genetic variants of SARS-CoV-2 on a population level. Our methodology provides a blueprint for rapid, unbiased, and cost-efficient genomic surveillance of SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the SIB Swiss Institute of Bioinformatics as a Competitive Resource, the Swiss National Science Foundation Special Call on Coronaviruses 31CA30 196538), Swiss Federal Office of Public Health, Eawag discretionary funds and an EPFL COVID19 grant. XFC was a fellow of the EU Horizon 2020 research and innovation programme under the Marie Skłodowska Curie Grant Agreement No. 754462. TS acknowledges funding from the Swiss National Science foundation (Special Call on Coronaviruses; 31CA30 196267).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approvals were necessary for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA version of the wastewater sequencing data with the human reads removed is available on the Sequence Read Archive (SRA) under project accession number PRJEB44932